Alan R. Crossman - Publications

Affiliations: 
The University of Manchester, Manchester, England, United Kingdom 
Area:
neurodegenerative disorders

174 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Fridjonsdottir E, Shariatgorji R, Nilsson A, Vallianatou T, Odell LR, Schembri LS, Svenningsson P, Fernagut PO, Crossman AR, Bezard E, Andrén PE. Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Science Advances. 7. PMID 33523980 DOI: 10.1126/sciadv.abe5948  0.96
2020 Bezard E, Li Q, Hulme H, Fridjonsdottir E, Nilsson A, Pioli E, Andren PE, Crossman AR. µ opioid receptor agonism for L-DOPA-induced dyskinesia in Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 32690616 DOI: 10.1523/JNEUROSCI.0610-20.2020  0.96
2015 Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, ... ... Crossman AR, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology. PMID 26209473 DOI: 10.1016/j.pneurobio.2015.07.002  0.96
2014 Shariatgorji M, Nilsson A, Goodwin RJ, Källback P, Schintu N, Zhang X, Crossman AR, Bezard E, Svenningsson P, Andren PE. Direct targeted quantitative molecular imaging of neurotransmitters in brain tissue sections. Neuron. 84: 697-707. PMID 25453841 DOI: 10.1016/j.neuron.2014.10.011  0.96
2014 Ko WK, Martin-Negrier ML, Bezard E, Crossman AR, Ravenscroft P. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiology of Disease. 70: 138-48. PMID 24969021 DOI: 10.1016/j.nbd.2014.06.013  0.96
2014 Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism & Related Disorders. 20: 452-5. PMID 24521874 DOI: 10.1016/j.parkreldis.2014.01.016  0.96
2014 Bourdenx M, Nilsson A, Wadensten H, Fälth M, Li Q, Crossman AR, Andrén PE, Bezard E. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia. Neurobiology of Disease. 62: 307-12. PMID 24148855 DOI: 10.1016/j.nbd.2013.10.016  0.96
2013 Obeso JA, Guridi J, Nambu A, Crossman AR. Motor manifestations and basal ganglia output activity: the paradox continues. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 416-8. PMID 23494928 DOI: 10.1002/mds.25358  0.96
2013 Kobylecki C, Crossman AR, Ravenscroft P. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia. Experimental Neurology. 247: 476-84. PMID 23360800 DOI: 10.1016/j.expneurol.2013.01.019  0.96
2011 Kobylecki C, Hill MP, Crossman AR, Ravenscroft P. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2354-63. PMID 21953539 DOI: 10.1002/mds.23867  0.96
2011 Fox SH, Brotchie JM. Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease Parkinson's Disease: Non-Motor and Non-Dopaminergic Features. 432-454. DOI: 10.1002/9781444397970.ch38  0.36
2010 Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. Journal of Neurochemistry. 114: 499-511. PMID 20456008 DOI: 10.1111/j.1471-4159.2010.06776.x  0.96
2010 Griffiths PD, Radon MR, Crossman AR, Zurakowski D, Connolly DJ. Anatomic localization of dyskinesia in children with "profound" perinatal hypoxic-ischemic injury. Ajnr. American Journal of Neuroradiology. 31: 436-41. PMID 19875467 DOI: 10.3174/ajnr.A1854  0.96
2008 Scholz B, Svensson M, Alm H, Sköld K, Fälth M, Kultima K, Guigoni C, Doudnikoff E, Li Q, Crossman AR, Bezard E, Andrén PE. Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. Plos One. 3: e1589. PMID 18270577 DOI: 10.1371/journal.pone.0001589  0.96
2008 Millan MJ, Svenningsson P, Ashby CR, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. The Journal of Pharmacology and Experimental Therapeutics. 324: 600-11. PMID 18024787 DOI: 10.1124/jpet.107.132563  0.96
2007 Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Experimental Neurology. 203: 415-22. PMID 17045989 DOI: 10.1016/j.expneurol.2006.08.026  0.96
2007 Aubert I, Guigoni C, Li Q, Dovero S, Bioulac BH, Gross CE, Crossman AR, Bloch B, Bezard E. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biological Psychiatry. 61: 836-44. PMID 16950226 DOI: 10.1016/j.biopsych.2006.06.038  0.96
2006 Kultima K, Scholz B, Alm H, Sköld K, Svensson M, Crossman AR, Bezard E, Andrén PE, Lönnstedt I. Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. Bmc Bioinformatics. 7: 475. PMID 17067368 DOI: 10.1186/1471-2105-7-475  0.96
2006 Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 2090-5. PMID 16991143 DOI: 10.1002/mds.21106  0.96
2006 Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou SB, Wang GJ, Ravenscroft P, Georges F, Crossman AR, Bezard E. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 8653-61. PMID 16928853 DOI: 10.1523/JNEUROSCI.2582-06.2006  0.96
2005 van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 1140-2. PMID 15894565 DOI: 10.1096/fj.04-3010fje  0.96
2005 Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 48: 503-16. PMID 15755478 DOI: 10.1016/j.neuropharm.2004.11.008  0.96
2005 Guigoni C, Li Q, Aubert I, Dovero S, Bioulac BH, Bloch B, Crossman AR, Gross CE, Bezard E. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2102-7. PMID 15728850 DOI: 10.1523/JNEUROSCI.5059-04.2005  0.96
2005 Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 403-9. PMID 15593312 DOI: 10.1002/mds.20345  0.96
2004 Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H. Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets. Clinical Neuropharmacology. 27: 171-7. PMID 15319703 DOI: 10.1097/01.wnf.0000135478.70905.3d  0.96
2004 Ismayilova N, Crossman A, Verkhratsky A, Brotchie J. Effects of adenosine A 1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats European Journal of Pharmacology. 497: 187-195. PMID 15306204 DOI: 10.1016/j.ejphar.2004.06.030  0.96
2004 Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 188: 471-9. PMID 15246846 DOI: 10.1016/j.expneurol.2004.05.004  0.96
2004 Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Experimental Neurology. 188: 128-38. PMID 15191809 DOI: 10.1016/j.expneurol.2004.03.022  0.96
2004 Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease Movement Disorders. 19: 554-560. PMID 15133820 DOI: 10.1002/mds.10693  0.96
2004 Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 310: 386-94. PMID 15004218 DOI: 10.1124/jpet.104.066191  0.96
2004 Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. The Journal of Pharmacology and Experimental Therapeutics. 309: 921-35. PMID 14978195 DOI: 10.1124/jpet.103.062414  0.96
2004 Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. European Journal of Pharmacology. 485: 159-64. PMID 14757136 DOI: 10.1016/j.ejphar.2003.11.065  0.96
2004 Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Experimental Neurology. 185: 36-46. PMID 14697317 DOI: 10.1016/j.expneurol.2003.09.001  0.96
2003 Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 1301-5. PMID 14639671 DOI: 10.1002/mds.10542  0.96
2003 Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Experimental Neurology. 183: 458-68. PMID 14552886 DOI: 10.1016/S0014-4886(03)00064-5  0.96
2003 Bezard E, Baufreton J, Owens G, Crossman AR, Dudek H, Taupignon A, Brotchie JM. Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 2337-8. PMID 14525941 DOI: 10.1096/fj.03-0291fje  0.96
2003 Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 872-83. PMID 12889076 DOI: 10.1002/mds.10464  0.96
2003 Segovia G, Mora F, Crossman AR, Brotchie JM. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 138-49. PMID 12539206 DOI: 10.1002/mds.10312  0.96
2003 Silverdale MA, Fox SH, Crossman AR, Brotchie JM. Potential nondopaminergic drugs for Parkinson's disease. Advances in Neurology. 91: 273-91. PMID 12442686  0.96
2002 Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of Cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Movement Disorders. 17: 1180-1187. PMID 12465055 DOI: 10.1002/mds.10289  0.96
2002 Silverdale MA, Crossman AR, Brotchie JM. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Experimental Neurology. 174: 21-8. PMID 11869030 DOI: 10.1006/exnr.2001.7854  0.96
2002 Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 145-9. PMID 11835452 DOI: 10.1002/mds.1280  0.96
2001 Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 57: 2108-11. PMID 11739835  0.96
2001 Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Experimental Neurology. 172: 189-98. PMID 11681851 DOI: 10.1006/exnr.2001.7763  0.96
2001 Henry B, Fox SH, Crossman AR, Brotchie JM. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Experimental Neurology. 171: 139-46. PMID 11520128 DOI: 10.1006/exnr.2001.7727  0.96
2001 Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 6853-61. PMID 11517273  0.96
2001 Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 642-50. PMID 11481687 DOI: 10.1002/mds.1148  0.96
2001 Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology. 169: 400-6. PMID 11358453 DOI: 10.1006/exnr.2001.7649  0.96
2001 Bentley DE, Youell PD, Crossman AR, Jones AK. Source localisation of 62-electrode human laser pain evoked potential data using a realistic head model. International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology. 41: 187-93. PMID 11325463 DOI: 10.1016/S0167-8760(01)00132-5  0.96
2001 Bezard E, Ravenscroft P, Gross CE, Crossman AR, Brotchie JM. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiology of Disease. 8: 343-50. PMID 11300729 DOI: 10.1006/nbdi.2000.0375  0.96
2001 Bezard E, Crossman AR, Gross CE, Brotchie JM. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 15: 1092-4. PMID 11292678  0.96
2000 Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 165: 136-42. PMID 10964492 DOI: 10.1006/exnr.2000.7444  0.96
2000 Crossman AR. Functional anatomy of movement disorders. Journal of Anatomy. 196: 519-25. PMID 10923984 DOI: 10.1017/S0021878299005981  0.96
2000 Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 14: 1432-8. PMID 10877836  0.96
1999 Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 744-53. PMID 10495035 DOI: 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7  0.96
1999 Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 155: 204-20. PMID 10072296 DOI: 10.1006/exnr.1998.6996  0.96
1998 Henry B, Crossman AR, Brotchie JM. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Advances in Neurology. 78: 53-61. PMID 9750903  0.96
1998 Brotchie JM, Henry B, Hille CJ, Crossman AR. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Advances in Neurology. 78: 41-52. PMID 9750902  0.96
1998 Crossman AR, Brotchie JM. Pathophysiology of dystonia. Advances in Neurology. 78: 19-25. PMID 9750899  0.96
1998 Richter A, Brotchie JM, Crossman AR, Löscher W. [3H]-2-deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 718-25. PMID 9686781 DOI: 10.1002/mds.870130419  0.96
1998 Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Experimental Neurology. 151: 334-42. PMID 9628768 DOI: 10.1006/exnr.1998.6819  0.96
1998 Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 228-33. PMID 9539334 DOI: 10.1002/mds.870130206  0.96
1998 Duty S, Henry B, Crossman AR, Brotchie JM. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 150: 223-34. PMID 9527891 DOI: 10.1006/exnr.1997.6771  0.96
1997 Maneuf YP, Crossman AR, Brotchie JM. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology. 148: 265-70. PMID 9398468 DOI: 10.1006/exnr.1997.6645  0.96
1996 Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse (New York, N.Y.). 22: 382-5. PMID 8867032 DOI: 10.1002/(SICI)1098-2396(199604)22:4<382::AID-SYN9>3.0.CO;2-7  0.96
1996 Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. European Journal of Pharmacology. 308: 161-4. PMID 8840127 DOI: 10.1016/0014-2999(96)00326-3  0.96
1996 Griffiths PD, Crossman AR. Autoradiography of transferrin receptors in the human brain. Neuroscience Letters. 211: 53-6. PMID 8809846 DOI: 10.1016/0304-3940(96)12719-1  0.96
1996 Maneuf YP, Duty S, Hille CJ, Crossman AR, Brotchie JM. Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Experimental Neurology. 139: 12-6. PMID 8635558 DOI: 10.1006/exnr.1996.0075  0.96
1995 Maneuf YP, Mitchell IJ, Crossman AR, Woodruff GN, Brotchie JM. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Research. 683: 102-8. PMID 7552334 DOI: 10.1016/0006-8993(95)00358-W  0.96
1994 Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Experimental Neurology. 125: 65-71. PMID 8307125 DOI: 10.1006/exnr.1994.1007  0.96
1994 Black MD, Crossman AR, Hayes AG, Elliott PJ. Acute and chronic behavioural sequelae resulting from intrastriatal injection of an NMDA agonist. Pharmacology, Biochemistry, and Behavior. 48: 441-6. PMID 8090812 DOI: 10.1016/0091-3057(94)90550-9  0.96
1994 Féger J, Bevan M, Crossman AR. The projections from the parafascicular thalamic nucleus to the subthalamic nucleus and the striatum arise from separate neuronal populations: a comparison with the corticostriatal and corticosubthalamic efferents in a retrograde fluorescent double-labelling study. Neuroscience. 60: 125-32. PMID 8052406 DOI: 10.1016/0306-4522(94)90208-9  0.96
1994 Griffiths PD, Perry RH, Crossman AR. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neuroscience Letters. 169: 68-72. PMID 8047295 DOI: 10.1016/0304-3940(94)90358-1  0.96
1994 Bevan MD, Bolam JP, Crossman AR. Convergent synaptic input from the neostriatum and the subthalamus onto identified nigrothalamic neurons in the rat. The European Journal of Neuroscience. 6: 320-34. PMID 8019671 DOI: 10.1111/j.1460-9568.1994.tb00275.x  0.96
1994 Bevan MD, Crossman AR, Bolam JP. Neurons projecting from the entopeduncular nucleus to the thalamus receive convergent synaptic inputs from the subthalamic nucleus and the neostriatum in the rat. Brain Research. 659: 99-109. PMID 7529649 DOI: 10.1016/0006-8993(94)90868-0  0.96
1993 Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia (Basel, Switzerland). 4: 61-5. PMID 8358514  0.96
1993 Graham WC, Sambrook MA, Crossman AR. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Research. 602: 290-303. PMID 8095431 DOI: 10.1016/0006-8993(93)90694-I  0.96
1993 Brotchie J, Crossman A, Mitchell I, Duty S, Carroll C, Cooper A, Henry B, Hughes N, Maneuf Y. Chemical signalling in the globus pallidus in parkinsonism Progress in Brain Research. 99: 125-139. PMID 7906423 DOI: 10.1016/S0079-6123(08)61342-4  0.96
1993 Page RD, Sambrook MA, Crossman AR. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey. Neuroscience. 55: 147-65. PMID 7688878 DOI: 10.1016/0306-4522(93)90462-O  0.96
1992 Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain : a Journal of Neurology. 115: 809-24. PMID 1628204  0.96
1992 Mitchell IJ, Crossman AR, Liminga U, Andren P, Gunne LM. Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey. Movement Disorders : Official Journal of the Movement Disorder Society. 7: 32-7. PMID 1557064 DOI: 10.1002/mds.870070106  0.96
1992 Black MD, Crossman AR. Changes in dopamine D1 and D2 receptor binding in the substantia nigra following intrastriatal injection of a retrograde neurotoxin (volkensin). Neuroscience Letters. 134: 180-2. PMID 1534159 DOI: 10.1016/0304-3940(92)90511-5  0.96
1992 Black MD, Carey F, Crossman AR, Relton JK, Rothwell NJ. Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat. Brain Research. 585: 135-40. PMID 1387336 DOI: 10.1016/0006-8993(92)91198-N  0.96
1992 Aziz TZ, Peggs D, Agarwal E, Sambrook MA, Crossman AR. Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. British Journal of Neurosurgery. 6: 575-82. PMID 1361741 DOI: 10.3109/02688699209002375  0.96
1992 Griffiths PD, Crossman AR. Receptor changes in the neocortex of post-mortem tissue in Parkinson's disease and Alzheimer's disease Dementia. 3: 239-246.  0.96
1991 Mitchell IJ, Brotchie JM, Brown GD, Crossman AR. Modeling the functional organization of the basal ganglia. A parallel distributed processing approach. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 189-204. PMID 1922123 DOI: 10.1002/mds.870060302  0.96
1991 Graham WC, Hill DR, Woodruff GN, Sambrook MA, Crossman AR. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. Neuroscience Letters. 131: 129-34. PMID 1791971 DOI: 10.1016/0304-3940(91)90353-U  0.96
1991 Robertson RG, Graham WC, Sambrook MA, Crossman AR. Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus. Brain Research. 563: 278-80. PMID 1786541 DOI: 10.1016/0006-8993(91)91545-C  0.96
1991 Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 288-92. PMID 1758446 DOI: 10.1002/mds.870060404  0.96
1991 Brotchie JM, Crossman AR. D-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents. Experimental Neurology. 113: 171-81. PMID 1651255 DOI: 10.1016/0014-4886(91)90173-A  0.96
1991 Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 133-8. PMID 1647492 DOI: 10.1002/mds.870060208  0.96
1990 Mitchell IJ, Luquin R, Boyce S, Clarke CE, Robertson RG, Sambrook MA, Crossman AR. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 49-54. PMID 2296259 DOI: 10.1002/mds.870050113  0.96
1990 Boyce S, Clarke CE, Luquin R, Peggs D, Robertson RG, Mitchell IJ, Sambrook MA, Crossman AR. Induction of chorea and dystonia in parkinsonian primates. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 3-7. PMID 2296255 DOI: 10.1002/mds.870050103  0.96
1990 Robertson RG, Clarke CA, Boyce S, Sambrook MA, Crossman AR. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography. Brain Research. 531: 95-104. PMID 2289139 DOI: 10.1016/0006-8993(90)90762-Z  0.96
1990 Percheron G, Parent A, Crossman A, Filion M, Mitchell IJ, Bedard P, Francois C, Yelnik J, Fenelon G. Anatomico-physiological substratum of akinesia in primates | SUBSTRAT ANATOMO-PHYSIOLOGIQUE DE L'AKINESIE CHEZ LE PRIMATE Revue Neurologique. 146: 575-584. PMID 2263820  0.96
1990 Graham WC, Robertson RG, Sambrook MA, Crossman AR. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sciences. 47: PL91-7. PMID 2250573 DOI: 10.1016/0024-3205(90)90376-3  0.96
1990 Graham WC, Clarke CE, Boyce S, Sambrook MA, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Research. 514: 103-10. PMID 2192772 DOI: 10.1016/0006-8993(90)90440-M  0.96
1990 Graham WC, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Research. 514: 93-102. PMID 2113410 DOI: 10.1016/0006-8993(90)90439-I  0.96
1990 Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 100-8. PMID 1970120 DOI: 10.1002/mds.870050203  0.96
1990 Griffiths PD, Sambrook MA, Perry R, Crossman AR. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. Journal of the Neurological Sciences. 100: 131-6. PMID 1965202 DOI: 10.1016/0022-510X(90)90023-G  0.96
1990 Bevan MD, Brotchie JM, Crossman AR. Intracerebral injections of the EAA antagonist kynurenate in the entopeduncular nucleus of the rat elicits a range of hyperkinetic disorders European Journal of Pharmacology. 183: 943.  0.96
1990 Mitchell IJ, Crossman AR. Antipsychotic drugs and tardive dyskinesia. Despite advances in our understanding of neurotransmitter systems in the brain, there is still no satisfactory explanation of why some patients receiving long-term neuroleptic treatment develop a syndrome of tardive dyskinesia Drug News and Perspectives. 3: 237-240.  0.96
1990 Brotchie JM, Bevan MD, Mitchell IJ, Crossman AR. Anti-parkinsonian effects of EAA antagonists in the entopeduncular nucleus are due to an action at NMDA-like receptors European Journal of Pharmacology. 183: 943-944.  0.96
1990 Crossman AR. To the editor: (II) Movement Disorders. 5: 266.  0.96
1989 Augood SJ, Emson PC, Mitchell IJ, Boyce S, Clarke CE, Crossman AR. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Brain Research. Molecular Brain Research. 6: 85-92. PMID 2788792 DOI: 10.1016/0169-328X(89)90032-6  0.96
1989 Clarke CE, Boyce S, Robertson RG, Sambrook MA, Crossman AR. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Journal of the Neurological Sciences. 90: 307-14. PMID 2786926 DOI: 10.1016/0022-510X(89)90117-2  0.96
1989 Crossman AR, Peggs D, Boyce S, Luquin MR, Sambrook MA. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology. 28: 1271-3. PMID 2687716 DOI: 10.1016/0028-3908(89)90221-9  0.96
1989 Graham WC, Robertson RG, Sambrook MA, Crossman AR. Extracellular amino acid levels in the globus pallidus of the conscious primate studied by intracerebral microdialysis. British Journal of Pharmacology. 98: 819P. PMID 2611525  0.96
1989 Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain : a Journal of Neurology. 112: 1533-48. PMID 2597995  0.96
1989 Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 32: 213-26. PMID 2586750 DOI: 10.1016/0306-4522(89)90120-6  0.96
1989 Crossman AR. Neural mechanisms in disorders of movement. Comparative Biochemistry and Physiology. a, Comparative Physiology. 93: 141-9. PMID 2568216 DOI: 10.1016/0300-9629(89)90201-6  0.96
1989 Robertson RG, Farmery SM, Sambrook MA, Crossman AR. Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Research. 476: 317-22. PMID 2539224 DOI: 10.1016/0006-8993(89)91252-3  0.96
1988 Leenders KL, Aquilonius SM, Bergström K, Bjurling P, Crossman AR, Eckernas SA, Gee AG, Hartvig P, Lundqvist H, LÃ¥ngström B. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Research. 445: 61-7. PMID 3259152 DOI: 10.1016/0006-8993(88)91074-8  0.96
1988 Crossman AR, Mitchell IJ, Sambrook MA, Jackson A. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. Brain : a Journal of Neurology. 111: 1211-33. PMID 3179691  0.96
1988 Clarke CE, Boyce S, Sambrook MA, Stahl SM, Crossman AR. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn-Schmiedeberg's Archives of Pharmacology. 338: 35-8. PMID 2907097 DOI: 10.1007/BF00168809  0.96
1987 Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Journal of the Neurological Sciences. 78: 273-80. PMID 3495642 DOI: 10.1016/0022-510X(87)90041-4  0.96
1987 Cross AJ, Skan WJ, Slater P, Mitchell IJ, Crossman AR. Autoradiographic analysis of [3H]kainic acid binding in primate brain. Journal of Receptor Research. 7: 775-97. PMID 3131516 DOI: 10.3109/10799898709054561  0.96
1987 Crossman AR, Clarke CE, Boyce S, Robertson RG, Sambrook MA. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 14: 428-35. PMID 3119180  0.96
1987 Crossman AR. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience. 21: 1-40. PMID 2955248 DOI: 10.1016/0306-4522(87)90322-8  0.96
1987 Graham WC, Crossman AR. Autoradiographic localization of dopamine D1 binding sites in areas receiving striatal input. European Journal of Pharmacology. 142: 479-81. PMID 2892688 DOI: 10.1016/0014-2999(87)90093-8  0.96
1987 Clarke CE, Boyce S, Sambrook MA, Crossman AR. Timing of levodopa therapy: evidence from MPTP-treated primates. Lancet. 1: 625. PMID 2881156 DOI: 10.1016/S0140-6736(87)90260-1  0.96
1986 Stuart AM, Mitchell IJ, Slater P, Unwin HL, Crossman AR. A semi-quantitative atlas of 5-hydroxytryptamine-1 receptors in the primate brain. Neuroscience. 18: 619-39. PMID 3748377 DOI: 10.1016/0306-4522(86)90058-8  0.96
1986 Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neuroscience Letters. 63: 61-5. PMID 3485267 DOI: 10.1016/0304-3940(86)90013-3  0.96
1986 Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism. Journal of Neural Transmission. Supplementum. 20: 41-6. PMID 3462325  0.96
1985 Patel S, Slater P, Crossman AR. A lesioning and 2-deoxyglucose study of the hyperactivity produced by an intra-accumbens dopamine agonist. Naunyn-Schmiedeberg's Archives of Pharmacology. 331: 334-40. PMID 4094623 DOI: 10.1007/BF00500815  0.96
1985 Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Research. 339: 346-50. PMID 4027631 DOI: 10.1016/0006-8993(85)90102-7  0.96
1985 Mitchell IJ, Sambrook MA, Crossman AR. Subcortical changes in the regional uptake of [3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-aminobutyric acid antagonist into the subthalamic nucleus. Brain : a Journal of Neurology. 108: 405-22. PMID 4005529  0.96
1985 Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neuroscience Letters. 61: 195-200. PMID 3878482 DOI: 10.1016/0304-3940(85)90424-0  0.96
1985 Crossman AR, Mitchell IJ, Sambrook MA. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology. 24: 587-91. PMID 3875056 DOI: 10.1016/0028-3908(85)90070-X  0.96
1985 Romanowski CA, Mitchell IJ, Crossman AR. The organisation of the efferent projections of the zona incerta. Journal of Anatomy. 143: 75-95. PMID 3870735  0.96
1984 Jackson A, Crossman AR. Experimental choreoathetosis produced by injection of a gamma-aminobutyric acid antagonist into the lentiform nucleus in the monkey. Neuroscience Letters. 46: 41-5. PMID 6728327 DOI: 10.1016/0304-3940(84)90196-4  0.96
1984 Mitchell IJ, Crossman AR. In defence of optical density ratios in 2-deoxyglucose autoradiography. Brain Research. 298: 191-2. PMID 6722556 DOI: 10.1016/0006-8993(84)91168-5  0.96
1984 Crossman AR, Sambrook MA, Jackson A. Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. Brain : a Journal of Neurology. 107: 579-96. PMID 6722517  0.96
1984 Mitchell IJ, Stuart AM, Slater P, Unwin HP, Crossman AR. Autoradiographic demonstration of 5HT1 binding sites in the primate basal nucleus of Meynert. European Journal of Pharmacology. 104: 189-90. PMID 6499916 DOI: 10.1016/0014-2999(84)90390-X  0.96
1984 Féger J, Crossman AR. Identification of different subpopulations of neostriatal neurones projecting to globus pallidus or substantia nigra in the monkey: a retrograde fluorescence double-labelling study. Neuroscience Letters. 49: 7-12. PMID 6493600 DOI: 10.1016/0304-3940(84)90127-7  0.96
1983 Needham GA, Soden PD, Sambrook MA, Crossman AR. A remotely operated pump for intracerebral micro-injection in the primate. Journal of Neuroscience Methods. 7: 281-8. PMID 6843169 DOI: 10.1016/0165-0270(83)90011-0  0.96
1983 Jackson A, Crossman AR. Nucleus tegmenti pedunculopontinus: efferent connections with special reference to the basal ganglia, studied in the rat by anterograde and retrograde transport of horseradish peroxidase. Neuroscience. 10: 725-65. PMID 6646427 DOI: 10.1016/0306-4522(83)90213-0  0.96
1983 Hammond C, Rouzaire-Dubois B, Féger J, Jackson A, Crossman AR. Anatomical and electrophysiological studies on the reciprocal projections between the subthalamic nucleus and nucleus tegmenti pedunculopontinus in the rat. Neuroscience. 9: 41-52. PMID 6308507 DOI: 10.1016/0306-4522(83)90045-3  0.96
1983 Rouzaire-Dubois B, Scarnati E, Hammond C, Crossman AR, Shibazaki T. Microiontophoretic studies on the nature of the neurotransmitter in the subthalamo-entopeduncular pathway of the rat. Brain Research. 271: 11-20. PMID 6136313 DOI: 10.1016/0006-8993(83)91360-4  0.96
1983 Crossman AR, Latham A, Longman DA. Motor dysfunction induced by application of GABA antagonists to the subthalamic nucleus of rat brain Journal of Physiology. 85P.  0.96
1982 Slater P, Crossman AR, Sambrook MA. Autoradiographic demonstration of binding sites for [3H]desipramine in rat brain. Neuroscience Letters. 31: 259-63. PMID 7133561 DOI: 10.1016/0304-3940(82)90030-1  0.96
1981 Jackson A, Crossman AR. Subthalamic nucleus efferent projection to the cerebral cortex. Neuroscience. 6: 2367-77. PMID 7329552 DOI: 10.1016/0306-4522(81)90023-3  0.96
1981 Jackson A, Crossman AR. Basal ganglia and other afferent projections to the peribrachial region in the rat: a study using retrograde and anterograde transport of horseradish peroxidase. Neuroscience. 6: 1537-49. PMID 7266877 DOI: 10.1016/0306-4522(81)90223-2  0.96
1981 Jackson A, Crossman AR. Subthalamic projection to nucleus tegmenti pedunculopontinus in the rat. Neuroscience Letters. 22: 17-22. PMID 6164022 DOI: 10.1016/0304-3940(81)90278-0  0.96
1981 Lee LA, Slater P, Crossman AR. The role of the substantia nigra in a striatally-evoked motor response in the rat: effects of intranigral drugs and lesions. Neuroscience. 6: 359-66. PMID 6164012 DOI: 10.1016/0306-4522(81)90129-9  0.96
1981 Jackson A, Crossman AR. The efferent projections of the entopeduncular nucleus in the rat: A study using anterograde and retrograde transport of HRP Neuroscience Letters. 24: S127.  0.96
1981 Crossman AR, Feger J, Hammond C. Studies on site specificity of intracerebral durg injection in the production of experimental hemiballismus in the monkey Journal of Physiology. 109P-110P.  0.96
1980 Crossman AR, Sambrook MA, Jackson A. Experimental hemiballismus in the baboon produced by injection of a gamma-aminobutyric acid antagonist into the basal ganglia. Neuroscience Letters. 20: 369-72. PMID 7443083 DOI: 10.1016/0304-3940(80)90176-7  0.96
1980 Lee LA, Crossman AR, Slater P. The neurological basis of striatally induced head-turning in the rat: the effects of lesions in putative output pathways. Neuroscience. 5: 73-9. PMID 7366844 DOI: 10.1016/0306-4522(80)90072-X  0.96
1980 Crossman AR, Dickinson S, Longman DA, Slater P. Apparatus for measuring limb tonicity in the rat: application to the study of morphine-induced rigidity [proceedings]. The Journal of Physiology. 298: 15P-16P. PMID 7359383  0.96
1980 Slater P, Crossman AR. Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamine-induced unilateral nigro-striatal lesions. Neuropharmacology. 19: 289-95. PMID 7191487 DOI: 10.1016/0028-3908(80)90152-5  0.96
1980 Slater P, Lee LA, Longman DA, Crossman AR. An in vivo method for testing putative GABA-like compounds. Journal of Pharmacological Methods. 3: 39-49. PMID 6103084 DOI: 10.1016/0160-5402(80)90063-7  0.96
1980 Slater P, Blundell C, Crossman AR. The effects of narcotic analgesics on the turning behaviour of rats with 6-hydroxydopamine-induced unilateral nigro-striatal lesions. Neuropharmacology. 19: 187-93. PMID 6102357 DOI: 10.1016/0028-3908(80)90137-9  0.96
1980 Crossman AR, Sambrook MA, Jackson A. Choreoid hyperkinesia in the baboon following injection of picrotoxin into the basal ganglia Neuroscience Letters. 19: S335.  0.96
1979 Sambrook MA, Crossman AR, Slater P. Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway. Experimental Neurology. 63: 583-93. PMID 107039 DOI: 10.1016/0014-4886(79)90173-0  0.96
1979 Crossman AR, Lee LA, Longman DA, Slater P. Effects of benzodiazepines and barbiturates in a GABA-dependent animal model: interactions with muscimol in the globus pallidus [proceedings]. British Journal of Pharmacology. 66: 493P-494P. PMID 43183  0.96
1978 Crossman AR, Lee LA, Slater P. Effects of intrapallidal administration of convulsant drugs on head-turning evoked by striatal stimulation in rats [proceedings]. British Journal of Pharmacology. 64: 381P-382P. PMID 719239  0.96
1978 Crossman AR, Sambrook MA. The neurological basis of motor asymmetry following unilateral nigrostriatal lesions in the rat: the effect of secondary superior colliculus lesions. Brain Research. 159: 211-3. PMID 569529 DOI: 10.1016/0006-8993(78)90121-X  0.96
1978 Crossman AR, Sambrook MA. Experimental torticollis in the monkey produced by unilateral 6-hydroxy-dopamine brain lesions. Brain Research. 149: 498-502. PMID 96912 DOI: 10.1016/0006-8993(78)90492-4  0.96
1977 Williams DJ, Crossman AR, Slater P. The efferent projections of the nucleus accumbens in the rat. Brain Research. 130: 217-27. PMID 884524 DOI: 10.1016/0006-8993(77)90271-2  0.96
1977 Crossman AR, Sambrook MA, Gergies SW, Slater P. The neurological basis of motor asymmetry following unilateral 6-hydroxydopamine brain lesions in the rat: the effect of motor decortication. Journal of the Neurological Sciences. 34: 407-14. PMID 591996 DOI: 10.1016/0022-510X(77)90156-3  0.96
1977 Crossman AR, Lee LA, Slater P. Effects of manipulating pallidal and nigral GABA on striatally-mediated head-turning in the rat [proceedings]. British Journal of Pharmacology. 61: 483P. PMID 563262  0.96
1977 Crossman AR, Lee LA, Slater P. A method for investigating neurotransmission in the basal ganglia using combined stimulation and intracerebral drug injection [proceedings]. British Journal of Pharmacology. 61: 488P. PMID 201329  0.96
1976 Blundell C, Crossman AR, Slater P. The effect of morphine on turning behaviour in rats and mice with unilateral 6-hydroxydopamine lesions [proceedings]. British Journal of Pharmacology. 57: 456P. PMID 987818  0.96
1974 Woodruff GN, Elkhawad AO, Crossman AR, Walker RJ. Further evidence for the stimulation of rat brain dopamine receptors by a cyclic analogue of dopamine. The Journal of Pharmacy and Pharmacology. 26: 740-1. PMID 4155756  0.96
1974 Crossman AR, Walker RJ, Woodruff GN. Proceedings: Pharmacological studies on single neurones in the substantia nigra of the rat. British Journal of Pharmacology. 51: 137P-138P. PMID 4155331  0.96
1974 Woodruff GN, Elkhawad AO, Crossman AR. Further evidence for the stimulation of rat brain dopamine receptors by ergometrine. The Journal of Pharmacy and Pharmacology. 26: 455-6. PMID 4154992  0.96
1974 Crossman AR, Walker RJ, Woodruff GN. Problems associated with iontophoretic studies in the caudate nucleus and substantia nigra. Neuropharmacology. 13: 547-52. PMID 4153846 DOI: 10.1016/0028-3908(74)90144-0  0.96
1973 Crossman AR, el-Khawad AO, Walker RJ, Woodruff GN. Effects of ergometrine on dopamine receptors. The Journal of Physiology. 232: 59P. PMID 4727091  0.96
1973 Crossman AR, Walker RJ, Woodruff GN. Picrotoxin antagonism of gamma-aminobutyric acid inhibitory responses and synaptic inhibition in the rat substantia nigra. British Journal of Pharmacology. 49: 696-8. PMID 4362811  0.96
1972 Crossman AR, Kerkut GA, Walker RJ. Electrophysiological studies on the axon pathways of specified nerve cells in the central ganglia of two insect species, Periplaneta americana and Schistocerca gregaria Comparative Biochemistry and Physiology -- Part a: Physiology. 43: 393-415. DOI: 10.1016/0300-9629(72)90199-5  0.96
1971 Crossman AR, Kerkut GA, Walker RJ. Axon pathways of electrically excitable nerve cell bodies in the insect central nervous system. The Journal of Physiology. 218: 55P-56P. PMID 5130634  0.96
1971 Walker RJ, Crossman AR, Woodruff GN, Kerkut GA. The effect of bicuculline on the gamma-aminobutyric acid (GABA) receptors of neurons of Periplaneta americana and Helix aspersa. Brain Research. 33: 75-82. PMID 4330215 DOI: 10.1016/0006-8993(71)90306-4  0.96
1971 Crossman AR, Kerkut GA, Pitman RM, Walker RJ. Electrically excitable nerve cell bodies in the central ganglia of two insect species Periplaneta americana and Schistocerca gregaria. Investigation of cell geometry and morphology by intracellular dye injection Comparative Biochemistry and Physiology -- Part a: Physiology. 40: 579-582,IN1-IN2,583-. DOI: 10.1016/0300-9629(71)90242-8  0.96
Show low-probability matches.